Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-Expressing Hematologic Malignancies

NCT02924402 is registered in ClinicalTrials.gov with Xencor, Inc. as lead sponsor.

NCT NCT02924402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02924402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-Expressing Hematologic Malignancies
Lead sponsor
Xencor, Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2016
Completion date
April 30, 2024
Enrollment
154 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkins lymphoma, chronic lymphocytic leukemia